SLC5A2 and heart failure: Notably, the 34% lower heart failure risk versus sodium-glucose cotransporter-2 inhibitors (SGLT2i) challenges conventional hierarchies in diabetes care, suggesting complementary mechanisms—such as GLP-1 RA–mediated improvements in ventricular filling pressures37—that warrant further investigation.